KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...

HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital Partners (WA:CPAP) III, L.P. and associated entities. According to a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CEO of KalVista. "This is especially critical for vulnerable populations, such as those experiencing laryngeal attacks or adolescents whose only approved options are injectable on-demand treatments.

KALVISTA PHARMACEUTICALS ($KALV) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of -$0.92 per share, missing estimates of ...

KalVista Pharmaceuticals Stock Performance Shares of KALV stock opened at $11.92 on Friday. The firm’s 50 day moving average price is $9.31 and its 200-day moving average price is $10.31 ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update. "Sebetralstat is poised to ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each ...